Amgen recalls Epogen, Procrit
Amgen said that the lamellae result from the interaction of the formulation with glass vials over the shelf life of the product. Epogen and Procrit are indicated for
The European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) from Pfizer and Valneva for their Lyme disease vaccine candidate, PF-07307405.